TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2127040

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (2 X 600 mg/d)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pentoxifylline plus psychological training
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (2 X 600 mg/d) and psychological training
Number of subjects: 120
Study: 7037184

Group type: EXPERIMENTAL
Intervention: Cefuroxime (0.75 gm) every eight hours for five to ten days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cefazolin (1 gm) every eight hours for five to ten days
Number of subjects: 58
Study: 12202415

Group type: EXPERIMENTAL
Intervention: Intramuscular hCG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular progesterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral estrogen added to progesterone
Number of subjects: 0
Study: 30183430

Group type: EXPERIMENTAL
Intervention: Electromagnetic transduction therapy (EMTT) + Extracorporeal shock wave therapy (ESWT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Extracorporeal shock wave therapy (ESWT) with sham-EMTT
Number of subjects: 86
Study: 25744274

Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 µg/day) combined with a liberal sodium diet (∼200 mmol Na(+)/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 µg/day) combined with dietary sodium restriction (target: 50 mmol Na(+)/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo combined with a liberal sodium diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo combined with dietary sodium restriction
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 µg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sub-population (N = 9)
Number of subjects: 50
Study: 24781567

Group type: EXPERIMENTAL
Intervention: Light sedation (BIS >80)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Deep sedation (BIS approximately 50)
Number of subjects: 2
Study: 21823994

Group type: EXPERIMENTAL
Intervention: Superficial heat
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cold therapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Heating pad
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Contrast therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 34
Study: 20551461

Group type: EXPERIMENTAL
Intervention: 60 mg semapimod intravenously for 1 day with placebo for 2 days
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 60 mg semapimod intravenously for 3 days
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Cumulative dosing of semapimod > or = 360 mg
Number of subjects: 152
Study: 19099570

Group type: EXPERIMENTAL
Intervention: Tablets
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Lifestyle changes (diet)
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Suppositories
Number of subjects: 645
Study: 15688090

Group type: EXPERIMENTAL
Intervention: Acute phenylalanine and tyrosine depletion (APTD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo amino acid drinks
Number of subjects: 20
Study: 11830525

Group type: EXPERIMENTAL
Intervention: Δ13 present
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: IFN treatment among patients with Δ13
Number of subjects: 325
Study: 9835524

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice a day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7857216

Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg/po/d
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg/po/d in MRVT
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 18
Study: 2632716

Group type: EXPERIMENTAL
Intervention: Alcohol (0.75 g/kg body weight, diluted in orange juice)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 7
Study: 1104043

Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 32
Study: 31636806

Group type: EXPERIMENTAL
Intervention: L-carnitine-L-tartrate 1500 mg per day (n = 11)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 20
Study: 28286306

Group type: EXPERIMENTAL
Intervention: Cryopreserved amniotic membrane (AM) transplant during strabismus reoperation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no AM wrap)
Number of subjects: 30
Study: 26523787

Group type: EXPERIMENTAL
Intervention: Housing First intervention (At Home/Chez Soi project)
Number of subjects: 14
Study: 23151422

Group type: EXPERIMENTAL
Intervention: US-guided technique
Number of subjects: 104

Group type: COMPARATOR
Intervention: Doppler-assisted technique
Number of subjects: 104
Study: 21615472

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied to half of each IH once every other night for 16 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (untreated half of IH)
Number of subjects: 44
Study: 19629021

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17285204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Tropisetron 0.5 mg/m2
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Tropisetron 1.0 mg/m2
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Tropisetron 1.5 mg/m2
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Tropisetron 2.0 mg/m2
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Tropisetron (all doses)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Tropisetron (0.5, 1.0, 1.5, 2.0 mg/m2)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Tropisetron (0.5 mg/m2)
Number of subjects: 125
Study: 15591855

Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Etomidate (0.2 mg/kg)
Number of subjects: 34
Study: 11414005

Group type: EXPERIMENTAL
Intervention: Contextual version of Wason's selection task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abstract version of Wason's selection task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wason's selection task with negatives
Number of subjects: 0
Study: 9429523

Group type: EXPERIMENTAL
Intervention: Nasal wash
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nasopharyngeal wash
Number of subjects: 66
Study: 7712670

Group type: EXPERIMENTAL
Intervention: R-oxprenolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: S-oxprenolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: R-oxprenolol glucuronide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: S-oxprenolol glucuronide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Comparison of R- and S-oxprenolol glucuronides
Number of subjects: 8
Study: 2545455

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (100 micrograms to 4000 micrograms)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (500 micrograms and above)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 7
Study: 144508

Group type: EXPERIMENTAL
Intervention: High doses of sodium aurothiomalate (150 mg weekly)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional doses of sodium aurothiomalate (50 mg weekly)
Number of subjects: 47
Study: 31283023

Group type: EXPERIMENTAL
Intervention: LGVS (right vestibular stimulation)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham (placebo stimulation)
Number of subjects: 36
Study: 28002208

Group type: EXPERIMENTAL
Intervention: Individualized follow-up
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 112
Study: 25396334

Group type: EXPERIMENTAL
Intervention: 70 kVp/30 mL CCTA
Number of subjects: 150

Group type: COMPARATOR
Intervention: 80 kVp/60 mL CCTA
Number of subjects: 150

Group type: COMPARATOR
Intervention: 100 kVp/60 mL CCTA
Number of subjects: 150
Study: 22994579

Group type: EXPERIMENTAL
Intervention: Nutraceutical combination with Orthosiphon stamineus
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nutraceutical combination without Orthosiphon stamineus
Number of subjects: 30
Study: 19804400

Group type: EXPERIMENTAL
Intervention: Migraineurs (n=50)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Controls (n=38)
Number of subjects: 88
Study: 19183308

Group type: EXPERIMENTAL
Intervention: Low-fat meal (2 g fat, 320 kcal)
Number of subjects: 7

Group type: COMPARATOR
Intervention: High-fat meal (38 g fat, 640 kcal)
Number of subjects: 7
Study: 15996257

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 16

Group type: COMPARATOR
Intervention: No infliximab
Number of subjects: 16
Study: 12562740

Group type: EXPERIMENTAL
Intervention: Comorbid personality disorder
Number of subjects: 670
Study: 10690130

Group type: EXPERIMENTAL
Intervention: DCLHb 50 mg kg‐1 i.v.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: DCLHb 100 mg kg‐1 i.v.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: DCLHb 200 mg kg‐1 i.v.
Number of subjects: 34
Study: 8556095

Group type: EXPERIMENTAL
Intervention: Medically unexplained constipation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other functional bowel symptoms (diarrhea, bloating, abdominal pain)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Major depression and panic disorder
Number of subjects: 0
Study: 1695298

Group type: EXPERIMENTAL
Intervention: Isradipine (2.5‐5.0 mg b.i.d.)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5‐25 mg b.i.d.)
Number of subjects: 800
Study: 316459

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propoxyphene
Number of subjects: 30
Study: 31136431

Group type: EXPERIMENTAL
Intervention: New oral anticoagulants
Number of subjects: 32663

Group type: COMPARATOR
Intervention: LMWH
Number of subjects: 32663
Study: 28919061

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 833

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 833
Study: 24925985

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 141

Group type: COMPARATOR
Intervention: Antidepressant medication (paroxetine)
Number of subjects: 141
Study: 23344769

Group type: EXPERIMENTAL
Intervention: 10 mg rt-PA (group A)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 5 mg rt-PA (group B)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 10 mg and 5 mg rt-PA (both groups)
Number of subjects: 103
Study: 21300299

Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation (CR) program for 6 months
Number of subjects: 75

Group type: COMPARATOR
Intervention: Generic instructions for maintaining physical activity and a correct lifestyle (Control)
Number of subjects: 75
Study: 19996045

Group type: EXPERIMENTAL
Intervention: Healthy Choices (motivational interviewing intervention)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Specialty care alone (control)
Number of subjects: 186
Study: 16759048

Group type: COMPARATOR
Intervention: Empirical therapy
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Guidance by genotypic resistance results
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Salvage therapy with less daily doses
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: More pronounced 3-month viral load drop
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Overall survival without new AIDS events/death
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Previous AIDS events
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Higher baseline viral load
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Less pronounced 3-month viral load drop
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Baseline protease substitutions K20M/R and 184V
Number of subjects: 174
Study: 14716794

Group type: EXPERIMENTAL
Intervention: Suction drainage (group 1; n = 58)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: No drain with fibrin sealant (group 2; n = 29)
Number of subjects: 116

Group type: COMPARATOR
Intervention: No drain with no intervention (group 3; n = 29)
Number of subjects: 116

Group type: COMPARATOR
Intervention: No drain (both group 2 and group 3)
Number of subjects: 116
Study: 11732951

Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide, 250 microg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nebulized isotonic sodium chloride solution, 1 mL (Control)
Number of subjects: 80
Study: 9209775

Group type: EXPERIMENTAL
Intervention: Sumatriptan suppository 12.5 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sumatriptan suppository 25 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sumatriptan suppository 50 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sumatriptan suppository 100 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sumatriptan suppository 50 mg (twice a day for 11 doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo suppository (twice a day for 11 doses)
Number of subjects: 36
Study: 8480688

Group type: EXPERIMENTAL
Intervention: 45 mg Zn (as gluconate)/d for 60 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3304688

Group type: EXPERIMENTAL
Intervention: VAP plus 2 years of oral maintenance chemotherapy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CMOPP
Number of subjects: 54
Study: 29206056

Group type: EXPERIMENTAL
Intervention: Single-use autoinjector
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Reusable autoinjector
Number of subjects: 97
Study: 26727163

Group type: EXPERIMENTAL
Intervention: TG4010 plus chemotherapy
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: TG4010 plus chemotherapy (TrPAL ≤ ULN)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: TG4010 plus chemotherapy (TrPAL > ULN)
Number of subjects: 222
Study: 24598493

Group type: EXPERIMENTAL
Intervention: FRC posts placed (Subgroup 1.1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: No posts (Subgroup 1.2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No root canal preparation (Subgroup 1.3)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FRC posts placed (Subgroup 2.1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: No posts (Subgroup 2.2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No root canal preparation (Subgroup 2.3)
Number of subjects: 120
Study: 23141853

Group type: EXPERIMENTAL
Intervention: Percutaneous intervention plus optimal medical therapy (PCI)
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Optimal medical therapy (MED) alone
Number of subjects: 2201

Group type: EXPERIMENTAL
Intervention: Adjudicated HF hospitalization
Number of subjects: 2201

Group type: EXPERIMENTAL
Intervention: Baseline HF
Number of subjects: 2201
Study: 20371820

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study: 18977955

Group type: EXPERIMENTAL
Intervention: RIX4414 coadministered at 2 and 4 months
Number of subjects: 484

Group type: COMPARATOR
Intervention: RIX4414 administered separately at 3 and 5 months
Number of subjects: 484
Study: 15719745

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISD, 15 mg, 4 times per day) alone (Group A)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISD, 15 mg, 4 times per day) plus Compound Salvia injection (CSI) (Group B)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISD, 15 mg, 4 times per day) plus vitamin C (Group C)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Group A (ISD alone)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Group B (ISD + CSI)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Group C (ISD + vitamin C)
Number of subjects: 84
Study: 12842299

Group type: EXPERIMENTAL
Intervention: Fetal Alcohol Syndrome group
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (matched for age and ethnicity with no history of prenatal alcohol exposure)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both groups during cued-navigation trials
Number of subjects: 8
Study: 11021737

Group type: EXPERIMENTAL
Intervention: Topotecan (2.3 mg/m2 per day for 5 days every 21 days) with ranitidine (150 mg twice daily for 4 days before day 1 of one of the first two courses and 150 mg given 2 h before the first topotecan dose)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Topotecan (2.3 mg/m2 per day for 5 days every 21 days) without ranitidine
Number of subjects: 13
Study: 8781290

Group type: EXPERIMENTAL
Intervention: Protein deprivation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Elderly patients with hypoalbuminemia and inflammatory syndrome
Number of subjects: 10
Study: 1478401

Group type: EXPERIMENTAL
Intervention: Paracentesis (4 L/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Spironolactone (225 to 300 mg/day) + Furosemide (40 to 80 mg/day)
Number of subjects: 53
Study: 6471773

Group type: EXPERIMENTAL
Intervention: beta-Interferon (Fiblaferon) treatment (10(5) U/kg daily for 3 weeks followed by 3 times a week for 21 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No beta-Interferon treatment
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (adriamycine, cyclophosphamide, vincristine, dacarbazine)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: beta-Interferon
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 72
Study: 31264493

Group type: EXPERIMENTAL
Intervention: ALL therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy control group without ALL
Number of subjects: 12
Study: 30051507

Group type: EXPERIMENTAL
Intervention: Smartphone application for Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study: 26863155

Group type: EXPERIMENTAL
Intervention: trans‐resveratrol‐based supplement (Longevinex®)
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study: 24684552

Group type: EXPERIMENTAL
Intervention: Belatacept (monthly) and sirolimus (daily) after alemtuzumab induction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Belatacept (monthly)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Belatacept-based regimens supplemented by oral immunosuppression
Number of subjects: 20

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 20
Study: 22933049

Group type: EXPERIMENTAL
Intervention: Epilepax® (test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lamictal® (reference formulation)
Number of subjects: 24
Study: 18930212

Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel electrocoagulation
Number of subjects: 191

Group type: COMPARATOR
Intervention: Suture (control group)
Number of subjects: 191
Study: 17601464

Group type: EXPERIMENTAL
Intervention: High-frequency whole-body vibration (WBV) at 20Hz for 3 minutes a day, 3 days a week for 3 months
Number of subjects: 69
Study: 15358571

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (CS) applied for 48 hours before prick-testing.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intradermal injection of methylprednisolone immediately after prick-testing.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (non-treated area for topical CS application).
Number of subjects: 13
Study: 11401000

Group type: EXPERIMENTAL
Intervention: Ziprasidone IM 20 mg
Number of subjects: 79

Group type: COMPARATOR
Intervention: Ziprasidone IM 2 mg
Number of subjects: 79
Study: 9543153

Group type: EXPERIMENTAL
Intervention: Isoproterenol (CD25 = 2.37 +/- 2.27 microg)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Isoproterenol (CD25 = 3.03 +/- 2.39 microg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Isoproterenol (CD25 = 1.01 +/- 1.17 microg)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Isoproterenol (CD25 = 3.44 +/- 2.24 microg)
Number of subjects: 87
Study: 8046805

Group type: EXPERIMENTAL
Intervention: Symptom-triggered therapy (chlordiazepoxide administered only in response to withdrawal symptoms)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Fixed-schedule therapy (standard course of chlordiazepoxide four times daily with additional medication as needed)
Number of subjects: 101
Study: 3054280

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg before test meals
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Acarbose treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cessation of acarbose treatment
Number of subjects: 13
Study: 30086709

Group type: EXPERIMENTAL
Intervention: 0.75 μg/kg DEX
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1 μg/kg DEX
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.25 μg/kg DEX
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.5 μg/kg DEX
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All DEX groups
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study: 27485252

Group type: EXPERIMENTAL
Intervention: Imagery cognitive bias modification (imagery CBM)
Number of subjects: 101
Study: 25399973

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/d)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Paclitaxel/Carboplatin (Carboplatin: AUC 5 mg × ml⁻¹ × min⁻¹, 21-day cycle; Paclitaxel: 200 mg/m², 21-day cycle)
Number of subjects: 51
Study: 24349389

Group type: EXPERIMENTAL
Intervention: Decaffeinated green coffee blend (NESCAFÉ Green Blend coffee; GB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pure chlorogenic acids (CGA)
Number of subjects: 60